Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Biosynth AG. (9/7/22). "Press Release: Biosynth Carbosynth, Vivitide and Pepscan Rebrand to Biosynth". Staad.

Organisations Organisation Biosynth Carbosynth (Group)
  Today Biosynth (since 9/22) (Group)
  Group Biosynth (since 9/22) (Group)
  Organisation 2 Pepscan (Group)
  Today Biosynth (since 9/22) (Group)
  Group Biosynth (since 9/22) (Group)
Products Product peptide synthesis
  Product 2 enzyme, research
Persons Person Spitz, Urs (Biosynth 201905 CEO)
  Person 2 Cossins, Aimee (Biosynth Carbosynth 202209 Media Relations)

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business.

Biosynth Carbosynth, vivitide and Pepscan are pleased to announce today their rebranding to Biosynth to match their parent group and the launch of their site at

Biosynth is a global supplier of critical products and services to the life sciences industry, across the areas of complex chemicals, quality peptides and key biological reagents. In combination with their research product portfolio of more than 600K catalog products across all three areas, Biosynth partners with customers from their first idea to finished product, across research, development and commercial supply of key materials.

The new branding evokes the unique combinations that Biosynth offers, where Products meet Services and where Chemistry meets Biology, Biosynth is at “The Edge of Innovation.”

Dr. Urs Spitz, CEO and President of Biosynth, said, “We are thrilled to be unveiling our new Biosynth brand today, and to be formally integrating Pepscan and vivitide into the organization. We have long been the go to provider of complex chemicals across carbohydrates, nucleoside, enzyme substrates and beyond, and now have such breadth across peptides. We knew it was the right time to bring us all together so our customers can go to one place for all their needs.”

About Biosynth

Biosynth is a supplier of critical materials, securing life sciences supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over half a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at

Other members of the Biosynth group are unaffected by the rebranding at this time.

Media Contacts

Aimee Cossins
+44 7984 525560

Record changed: 2023-08-09


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Biosynth (since 9/22) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top